Atara Biotherapeutics, Inc.
ATRA
$9.91
-$0.32-3.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 9.87M | 8.36M | 8.48M | 13.71M | 22.32M |
| Total Receivables | 318.00K | -- | 1.25M | 1.91M | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | -- | -- | -- | -- | -- |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 3.34M | 3.81M | 2.48M | 2.81M | 2.45M |
| Total Current Assets | 13.53M | 12.17M | 12.21M | 18.43M | 24.77M |
|
|
|||||
| Total Current Assets | 13.53M | 12.17M | 12.21M | 18.43M | 24.77M |
| Net Property, Plant & Equipment | 6.73M | 6.93M | 7.14M | 10.85M | 11.20M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 765.00K | 890.00K | 886.00K | 881.00K | 927.00K |
| Total Assets | 21.02M | 20.00M | 20.24M | 30.17M | 36.90M |
|
|
|||||
| Total Accounts Payable | 824.00K | 637.00K | 127.00K | 318.00K | 1.76M |
| Total Accrued Expenses | 3.12M | 2.60M | 3.30M | 5.11M | 8.95M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 1.10M | 1.01M | 1.03M | 1.95M | 2.24M |
| Total Finance Division Other Current Liabilities | 1.81M | 1.40M | 10.47M | 10.68M | 1.61M |
| Total Other Current Liabilities | 1.81M | 1.40M | 10.47M | 10.68M | 1.61M |
| Total Current Liabilities | 6.85M | 5.65M | 14.92M | 18.06M | 14.56M |
|
|
|||||
| Total Current Liabilities | 6.85M | 5.65M | 14.92M | 18.06M | 14.56M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 8.78M | 9.08M | 9.35M | 15.01M | 15.43M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 42.39M | 42.59M | 34.47M | 33.74M | 41.95M |
| Total Liabilities | 58.02M | 57.31M | 58.74M | 66.80M | 71.94M |
|
|
|||||
| Common Stock & APIC | 1.99B | 1.99B | 1.98B | 1.98B | 1.98B |
| Retained Earnings | -2.03B | -2.03B | -2.02B | -2.02B | -2.01B |
| Treasury Stock & Other | -2.00K | -- | 1.00K | 2.00K | -- |
| Total Common Equity | -37.00M | -37.31M | -38.50M | -36.63M | -35.04M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | -37.00M | -37.31M | -38.50M | -36.63M | -35.04M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | -37.00M | -37.31M | -38.50M | -36.63M | -35.04M |
|
|
|||||